Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous ferric derisomaltose for iron deficiency in adults with chronic pain
ACTRN12622000412730Phase 2Recruiting
- Sponsor
- Metro North Health
- Start
- Aug 2023
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in iron deficiency anemia (IDA) comparing Ferric derisomaltose with Placebo saline (2 arms). Primary endpoint: Fatigue. Started Aug 2023; status: recruiting.
02
Drugs
ferric derisomaltose
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on ACTRN12622000412730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622000412730.